Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral semaglutide 25 mg and 50 mg vs 14 mg in type 2 diabetes
NCT04707469Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Jan 2021
- Primary completion
- Mar 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
A Phase 3 trial of semaglutide in type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jan 2021; status: completed.
02
Drugs
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04707469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04707469.